Financials data is unavailable for this security.
View more
Year on year Mochida Pharmaceutical Co Ltd 's net income fell -31.61% from 6.65bn to 4.55bn despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 46.63% to 49.39%.
| Gross margin | 49.61% |
|---|---|
| Net profit margin | 4.34% |
| Operating margin | 5.07% |
| Return on assets | 2.88% |
|---|---|
| Return on equity | 3.54% |
| Return on investment | 3.41% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Mochida Pharmaceutical Co Ltd fell by 13.72bn. However, Cash Flow from Investing totalled 74.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 7.48bn for operations while cash used for financing totalled 6.39bn.
| Cash flow per share | 209.39 |
|---|---|
| Price/Cash flow per share | 16.84 |
| Book value per share | 3,641.81 |
|---|---|
| Tangible book value per share | 3,620.79 |
More ▼
Balance sheet in JPYView more
| Current ratio | 4.75 |
|---|---|
| Quick ratio | 3.50 |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -29.14%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 2.24% |
|---|---|
| Div growth rate (5 year) | -1.21% |
| Payout ratio (TTM) | 31.27% |
| EPS growth(5 years) | -9.84 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -15.69 |
More ▼
